Thus, by identifying all eligible studies, we performed this meta-analysis to re-evaluate the relationship between XPD polymorphisms (Lys751Gln and Asp312Asn) and clinical outcome (response and overall survival) in NSCLC patients treated with Pt-CP. This evidence concerns the gene ERCC2 and non-small cell lung carcinoma.